Drugs.com adds custom 3D animation

Share this article:
Drugs.com adds custom 3D animation
Drugs.com adds custom 3D animation

Drugs.com partnered with Understand.com, a 3D animation and patient education firm, to deliver branded video and education tools for consumers and its advertising partners.

Animation and educational content for a given brand will be developed on a custom basis with drugmakers, and will be placed on the Drugs.com site. The 3D animations will also be made available for use on pharma web properties, according to Rob Griffin, SVP of business development at Understand.com. The joint program, called The Mechanism For Action, is PhRMA compliant and designed "for consumers to take action," according to the Understand.com website.

Griffin said the content is PhRMA compliant in that pharma companies can give the animation and video materials to doctors for use with their patients, and it doesn't qualify as a gift since it's designated for educational purposes. The goal is to educate patients, and that new comprehension "will drive adherence and compliance," said Griffin.

Drugs.com posted a sample of the new content online, which features a six-step 3D video explaining how finasteride — the active ingredient in Merck's Propecia — works to regrow hair. "Ninety percent of the [mechanism of action animation] out there is targeted to doctors," said Griffin. "We want to educate the consumer."

Drugs.com joined the WebMD Health Network at the beginning of 2010, which provides WebMD with exclusive consumer advertising rights on the site, including all display or banner ads. The Drugs.com website is owned and operated by the Drugsite Trust, a privately held trust administered by two pharmacists in New Zealand, according to the website.
Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...